OBJECTIVE AND DESIGN: The study comprised three protocols. Protocol 1 compared a HPLC method with the commonly employed colorimetric diazocoupling method. Protocol 2 examined, if the last dosage of p-aminobenzoic acid (PABA) could be advanced in the old to allow for a delayed age-dependent urinary excretion of PABA. Protocol 3 established limits for recovery of PABA in 24 h urine applying the HPLC method. SUBJECTS AND SETTING: A total of 151 healthy volunteers participated in the study of which 140 were accepted. In protocol 1: 37 subjects aged 20-78 y were included. All subjects took PABA as recommended (80 mg orally at 08.00, 12.00 and 18.00 h). Protocol 2: compared urinary PABA excretion in two groups of 80 y old subjects who had their last PABA dosage administered at 15.00 h (n = 16) and at 18.00 h (n = 31), respectively. Protocol 3: comprised 56 subjects aged 20-80 y. In the younger age group (20-59 y; n = 34) PABA was taken as recommended, whereas in the older age group (60-80 y; n = 22) the last PABA dosage was advanced three hours. RESULTS: Protocol 1: HPLC gave significantly lower PABA recovery results compared to colorimetry, the difference between methods being 23.9 +/- 8.5 mg/24 h (P < 0.001). Protocol 2: higher PABA recoveries were demonstrated with the advanced dosage schedule compared to the recommended schedule (208 +/- 14 mg/24 h vs 181 +/- 22 mg/24 h; P < 0.001). Protocol 3: PABA recovery with HPLC was 211 +/- 12 mg/24 h, and the lower limit comprising 95% of subjects was 187 mg/24 h. Similar PABA recoveries were demonstrated in the younger subjects and the older subjects (211 +/- 11 mg/24 h vs 211 +/- 13 mg/24 h; NS). CONCLUSION: An advanced dosage schedule for PABA in the aged is recommended. Because of lower recoveries with HPLC, the low limit for recovered PABA in a complete 24 h urine differs from the limit based on colorimetry. This study found a limit of 187 mg/24 h corresponding to the lower 95% confidence limit for a single subject.
OBJECTIVE AND DESIGN: The study comprised three protocols. Protocol 1 compared a HPLC method with the commonly employed colorimetric diazocoupling method. Protocol 2 examined, if the last dosage of p-aminobenzoic acid (PABA) could be advanced in the old to allow for a delayed age-dependent urinary excretion of PABA. Protocol 3 established limits for recovery of PABA in 24 h urine applying the HPLC method. SUBJECTS AND SETTING: A total of 151 healthy volunteers participated in the study of which 140 were accepted. In protocol 1: 37 subjects aged 20-78 y were included. All subjects took PABA as recommended (80 mg orally at 08.00, 12.00 and 18.00 h). Protocol 2: compared urinary PABA excretion in two groups of 80 y old subjects who had their last PABA dosage administered at 15.00 h (n = 16) and at 18.00 h (n = 31), respectively. Protocol 3: comprised 56 subjects aged 20-80 y. In the younger age group (20-59 y; n = 34) PABA was taken as recommended, whereas in the older age group (60-80 y; n = 22) the last PABA dosage was advanced three hours. RESULTS: Protocol 1: HPLC gave significantly lower PABA recovery results compared to colorimetry, the difference between methods being 23.9 +/- 8.5 mg/24 h (P < 0.001). Protocol 2: higher PABA recoveries were demonstrated with the advanced dosage schedule compared to the recommended schedule (208 +/- 14 mg/24 h vs 181 +/- 22 mg/24 h; P < 0.001). Protocol 3: PABA recovery with HPLC was 211 +/- 12 mg/24 h, and the lower limit comprising 95% of subjects was 187 mg/24 h. Similar PABA recoveries were demonstrated in the younger subjects and the older subjects (211 +/- 11 mg/24 h vs 211 +/- 13 mg/24 h; NS). CONCLUSION: An advanced dosage schedule for PABA in the aged is recommended. Because of lower recoveries with HPLC, the low limit for recovered PABA in a complete 24 h urine differs from the limit based on colorimetry. This study found a limit of 187 mg/24 h corresponding to the lower 95% confidence limit for a single subject.
Authors: Stellena Mathiaparanam; Adriana Nori de Macedo; Andrew Mente; Paul Poirier; Scott A Lear; Andreas Wielgosz; Koon K Teo; Salim Yusuf; Philip Britz-Mckibbin Journal: Nutrients Date: 2022-06-21 Impact factor: 6.706
Authors: Laurence S Freedman; Victor Kipnis; Douglas Midthune; John Commins; Brian Barrett; Virag Sagi-Kiss; Susana A Palma-Duran; Carol S Johnston; Diane M O'Brien; Natasha Tasevska Journal: Cancer Epidemiol Biomarkers Prev Date: 2022-06-01 Impact factor: 4.090
Authors: Norm R C Campbell; Feng J He; Monique Tan; Francesco P Cappuccio; Bruce Neal; Mark Woodward; Mary E Cogswell; Rachael McLean; Joanne Arcand; Graham MacGregor; Paul Whelton; Antti Jula; Mary R L'Abbe; Laura K Cobb; Daniel T Lackland Journal: J Clin Hypertens (Greenwich) Date: 2019-05-14 Impact factor: 3.738
Authors: Natasa Tasevska; Douglas Midthune; Nancy Potischman; Amy F Subar; Amanda J Cross; Sheila A Bingham; Arthur Schatzkin; Victor Kipnis Journal: Cancer Epidemiol Biomarkers Prev Date: 2011-01-28 Impact factor: 4.254
Authors: Katherine A John; Mary E Cogswell; Norm R Campbell; Caryl A Nowson; Branka Legetic; Anselm J M Hennis; Sheena M Patel Journal: J Clin Hypertens (Greenwich) Date: 2016-01-03 Impact factor: 3.738
Authors: Mary E Cogswell; Joyce Maalouf; Paul Elliott; Catherine M Loria; Sheena Patel; Barbara A Bowman Journal: Annu Rev Nutr Date: 2015-05-06 Impact factor: 11.848
Authors: David J Baer; Kim S Stote; David R Paul; G Keith Harris; William V Rumpler; Beverly A Clevidence Journal: J Nutr Date: 2011-06-15 Impact factor: 4.798
Authors: Natasha Tasevska; Virag Sagi-Kiss; Susana A Palma-Duran; Brian Barrett; Matthew Chaloux; John Commins; Diane M O'Brien; Carol S Johnston; Douglas Midthune; Victor Kipnis; Laurence S Freedman Journal: Am J Clin Nutr Date: 2021-08-02 Impact factor: 8.472
Authors: Elske M Brouwer-Brolsma; Martinette T Streppel; Linde van Lee; Anouk Geelen; Diewertje Sluik; Anne M van de Wiel; Jeanne H M de Vries; Pieter van 't Veer; Edith J M Feskens Journal: Nutrients Date: 2017-10-18 Impact factor: 5.717